Caregiver Daily Reporting of Symptoms in Autism Spectrum Disorder: Observational Study Using Web and Mobile Apps.

affect autism spectrum disorder ecological momentary assessment mHealth mobile app patient reported outcome measures symptom assessment

Journal

JMIR mental health
ISSN: 2368-7959
Titre abrégé: JMIR Ment Health
Pays: Canada
ID NLM: 101658926

Informations de publication

Date de publication:
26 Mar 2019
Historique:
received: 28 06 2018
accepted: 31 12 2018
revised: 05 12 2018
entrez: 27 3 2019
pubmed: 27 3 2019
medline: 27 3 2019
Statut: epublish

Résumé

Currently, no medications are approved to treat core symptoms of autism spectrum disorder (ASD). One barrier to ASD medication development is the lack of validated outcome measures able to detect symptom change. Current ASD interventions are often evaluated using retrospective caregiver reports that describe general clinical presentation but often require recall of specific behaviors weeks after they occur, potentially reducing accuracy of the ratings. My JAKE, a mobile and Web-based mobile health (mHealth) app that is part of the Janssen Autism Knowledge Engine-a dynamically updated clinical research system-was designed to help caregivers of individuals with ASD to continuously log symptoms, record treatments, and track progress, to mitigate difficulties associated with retrospective reporting. My JAKE was deployed in an exploratory, noninterventional clinical trial to evaluate its utility and acceptability to monitor clinical outcomes in ASD. Hypotheses regarding relationships among daily tracking of symptoms, behavior, and retrospective caregiver reports were tested. Caregivers of individuals with ASD aged 6 years to adults (N=144) used the My JAKE app to make daily reports on their child's sleep quality, affect, and other self-selected specific behaviors across the 8- to 10-week observational study. The results were compared with commonly used paper-and-pencil scales acquired over a concurrent period at regular 4-week intervals. Caregiver reporting of behaviors in real time was successfully captured by My JAKE. On average, caregivers made reports 2-3 days per week across the study period. Caregivers were positive about their use of the system, with over 50% indicating that they would like to use My JAKE to track behavior outside of a clinical trial. More positive average daily reporting of overall type of day was correlated with 4 weekly reports of lower caregiver burden made at 4-week intervals (r=-0.27, P=.006, n=88) and with ASD symptoms (r=-0.42, P<.001, n=112). My JAKE reporting aligned with retrospective Web-based or paper-and-pencil scales. Use of mHealth apps, such as My JAKE, has the potential to increase the validity and accuracy of caregiver-reported outcomes and could be a useful way of identifying early changes in response to intervention. Such systems may also assist caregivers in tracking symptoms and behavior outside of a clinical trial, help with personalized goal setting, and monitoring of progress, which could collectively improve understanding of and quality of life for individuals with ASD and their families. ClinicalTrials.gov NCT02668991; https://clinicaltrials.gov/ct2/show/NCT02668991.

Sections du résumé

BACKGROUND BACKGROUND
Currently, no medications are approved to treat core symptoms of autism spectrum disorder (ASD). One barrier to ASD medication development is the lack of validated outcome measures able to detect symptom change. Current ASD interventions are often evaluated using retrospective caregiver reports that describe general clinical presentation but often require recall of specific behaviors weeks after they occur, potentially reducing accuracy of the ratings. My JAKE, a mobile and Web-based mobile health (mHealth) app that is part of the Janssen Autism Knowledge Engine-a dynamically updated clinical research system-was designed to help caregivers of individuals with ASD to continuously log symptoms, record treatments, and track progress, to mitigate difficulties associated with retrospective reporting.
OBJECTIVE OBJECTIVE
My JAKE was deployed in an exploratory, noninterventional clinical trial to evaluate its utility and acceptability to monitor clinical outcomes in ASD. Hypotheses regarding relationships among daily tracking of symptoms, behavior, and retrospective caregiver reports were tested.
METHODS METHODS
Caregivers of individuals with ASD aged 6 years to adults (N=144) used the My JAKE app to make daily reports on their child's sleep quality, affect, and other self-selected specific behaviors across the 8- to 10-week observational study. The results were compared with commonly used paper-and-pencil scales acquired over a concurrent period at regular 4-week intervals.
RESULTS RESULTS
Caregiver reporting of behaviors in real time was successfully captured by My JAKE. On average, caregivers made reports 2-3 days per week across the study period. Caregivers were positive about their use of the system, with over 50% indicating that they would like to use My JAKE to track behavior outside of a clinical trial. More positive average daily reporting of overall type of day was correlated with 4 weekly reports of lower caregiver burden made at 4-week intervals (r=-0.27, P=.006, n=88) and with ASD symptoms (r=-0.42, P<.001, n=112).
CONCLUSIONS CONCLUSIONS
My JAKE reporting aligned with retrospective Web-based or paper-and-pencil scales. Use of mHealth apps, such as My JAKE, has the potential to increase the validity and accuracy of caregiver-reported outcomes and could be a useful way of identifying early changes in response to intervention. Such systems may also assist caregivers in tracking symptoms and behavior outside of a clinical trial, help with personalized goal setting, and monitoring of progress, which could collectively improve understanding of and quality of life for individuals with ASD and their families.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT02668991; https://clinicaltrials.gov/ct2/show/NCT02668991.

Identifiants

pubmed: 30912762
pii: v6i3e11365
doi: 10.2196/11365
pmc: PMC6454343
doi:

Banques de données

ClinicalTrials.gov
['NCT02668991']

Types de publication

Journal Article

Langues

eng

Pagination

e11365

Informations de copyright

©Abigail Bangerter, Nikolay V. Manyakov, David Lewin, Matthew Boice, Andrew Skalkin, Shyla Jagannatha, Meenakshi Chatterjee, Geraldine Dawson, Matthew S Goodwin, Robert Hendren, Bennett Leventhal, Frederick Shic, Seth Ness, Gahan Pandina. Originally published in JMIR Mental Health (http://mental.jmir.org), 26.03.2019.

Références

J Fam Psychol. 2007 Mar;21(1):67-73
pubmed: 17371111
Front Neuroinform. 2017 Feb 16;11:9
pubmed: 28261082
Gerontologist. 1980 Dec;20(6):649-55
pubmed: 7203086
Behav Brain Sci. 2005 Oct;28(5):675-91; discussion 691-735
pubmed: 16262930
J Med Internet Res. 2013 Apr 18;15(4):e86
pubmed: 23598614
Autism. 2015 Jul;19(5):622-36
pubmed: 25096930
J Child Psychol Psychiatry. 2015 May;56(5):577-85
pubmed: 25243378
Qual Life Res. 2016 Mar;25(3):559-74
pubmed: 26334842
JMIR Res Protoc. 2017 Jun 16;6(6):e114
pubmed: 28623183
Front Neurosci. 2017 Sep 26;11:517
pubmed: 29018317
Nat Rev Drug Discov. 2016 Jan;15(1):70-3
pubmed: 26718285
Int J Dev Disabil. 2018 Jun 05;66(1):46-53
pubmed: 34141366
J Pers. 1996 Dec;64(4):959-91
pubmed: 8956519
Am J Intellect Dev Disabil. 2011 Jan;116(1):81-95
pubmed: 21291312
J Clin Child Adolesc Psychol. 2014;43(5):828-43
pubmed: 25216048
Res Autism Spectr Disord. 2016 Sep-Oct;29-30:57-65
pubmed: 28083073
Psychol Sci. 2003 May;14(3):207-14
pubmed: 12741742
J Autism Dev Disord. 2014 Jan;44(1):168-79
pubmed: 23748386
Contemp Clin Trials. 2015 Nov;45(Pt A):41-54
pubmed: 26176884
CNS Spectr. 2004 Jan;9(1):36-47
pubmed: 14999174
IPSN. 2014;2014:71-82
pubmed: 25531010
J Autism Dev Disord. 2013 Dec;43(12):2830-43
pubmed: 23624832
Perspect Psychol Sci. 2009 Jan;4(1):19-21
pubmed: 26158824
J Adolesc. 2014 Jan;37(1):37-46
pubmed: 24331303
NPJ Schizophr. 2017 Oct 16;3(1):37
pubmed: 29038553
Mol Autism. 2017 Jun 23;8:24
pubmed: 28649312
Am J Ment Retard. 2006 Mar;111(2):121-37
pubmed: 16466284
J Autism Dev Disord. 2003 Aug;33(4):427-33
pubmed: 12959421
Autism. 2016 Jul;20(5):623-7
pubmed: 26471427
PLoS Med. 2013;10(1):e1001363
pubmed: 23458994
Psychiatr Clin North Am. 1991 Mar;14(1):69-80
pubmed: 2047333
Clin Psychol Rev. 2010 Aug;30(6):794-804
pubmed: 20619520
Arch Gen Psychiatry. 2012 Mar;69(3):274-82
pubmed: 22065252
Children (Basel). 2017 May 16;4(5):
pubmed: 28509853
J Autism Dev Disord. 2012 Apr;42(4):531-8
pubmed: 21538171
J Dev Behav Pediatr. 2016 Jun;37(5):370-6
pubmed: 27244298
J Autism Dev Disord. 2006 Oct;36(7):849-61
pubmed: 16845581
Pediatrics. 2007 Feb;119 Suppl 1:S114-21
pubmed: 17272578
Control Clin Trials. 2003 Apr;24(2):182-99
pubmed: 12689739
J Child Adolesc Psychopharmacol. 2017 Nov;27(9):814-822
pubmed: 28498053
J Psychiatr Res. 2017 Feb;85:1-14
pubmed: 27814455
J Autism Dev Disord. 2014 Nov;44(11):2851-61
pubmed: 24902932
J Nepal Health Res Counc. 2018 Jul 03;16(2):184-189
pubmed: 29983435
J Am Acad Child Adolesc Psychiatry. 2003 Dec;42(12):1443-50
pubmed: 14627879
Autism. 2012 May;16(3):306-20
pubmed: 21705474
J Autism Dev Disord. 2000 Apr;30(2):99-111
pubmed: 10832774
J Autism Dev Disord. 2011 Jun;41(6):770-82
pubmed: 20839042
Nat Rev Drug Discov. 2013 Oct;12(10):777-90
pubmed: 24080699
Autism. 2015 Jan;19(1):38-52
pubmed: 24259748
J Autism Dev Disord. 2014 May;44(5):1103-16
pubmed: 24165702
Rev Lat Am Enfermagem. 2015 Jul-Aug;23(4):769-77
pubmed: 26444180
Arch Gen Psychiatry. 1976 Mar;33(3):292-301
pubmed: 769721
J Autism Dev Disord. 2011 Jul;41(7):926-37
pubmed: 20960041
Neuropsychiatr Dis Treat. 2016 Aug 04;12:1943-51
pubmed: 27536117
Autism Res. 2017 Jul;10(7):1221-1238
pubmed: 28301091
Arch Gen Psychiatry. 1972 Dec;27(6):816-22
pubmed: 4564954
J Autism Dev Disord. 2014 May;44(5):1128-43
pubmed: 24158679
J Autism Dev Disord. 2014 Jun;44(6):1332-46
pubmed: 24234677
Annu Rev Clin Psychol. 2008;4:1-32
pubmed: 18509902
Ann Behav Med. 2002 Summer;24(3):236-43
pubmed: 12173681

Auteurs

Abigail Bangerter (A)

Neuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, NJ, United States.

Nikolay V Manyakov (NV)

Computational Biology, Discovery Sciences, Janssen Research & Development, Beerse, Belgium.

David Lewin (D)

Clinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, United States.

Matthew Boice (M)

Neuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, NJ, United States.

Andrew Skalkin (A)

Informatics, Janssen Research & Development, LLC, Spring House, PA, United States.

Shyla Jagannatha (S)

Statistical Decision Sciences, Janssen Research & Development, LLC, Titusville, NJ, United States.

Meenakshi Chatterjee (M)

Computational Biology, Discovery Sciences, Janssen Research & Development, LLC, Spring House, PA, United States.

Geraldine Dawson (G)

Duke Center for Autism and Brain Development, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, United States.

Matthew S Goodwin (MS)

Department of Health Sciences, Northeastern University, Boston, MA, United States.

Robert Hendren (R)

Department of Psychiatry, School of Medicine, University of California, San Francisco, San Francisco, CA, United States.

Bennett Leventhal (B)

Department of Psychiatry, School of Medicine, University of California, San Francisco, San Francisco, CA, United States.

Frederick Shic (F)

Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, United States.

Seth Ness (S)

Neuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, NJ, United States.

Gahan Pandina (G)

Neuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, NJ, United States.

Classifications MeSH